ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Psychiatry

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

14,071Medicare Part D Prescriptions Filled, Including Refills

Rank: 3 out of 197

$1.8M Total Retail Price of All Prescriptions

Rank: 2 out of 197

616 Patients Receiving at Least One Drug in Part D
22%Patients 65 Years and Older
91% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Louisiana
Lower avg

Schedule Two
Controlled Substances

14% of this provider’s 616 patients filled at least one prescription for a schedule two drug, compared to an average of 2%.

Schedule Three
Controlled Substances

12% of this provider’s 616 patients filled at least one prescription for a schedule three drug, compared to an average of 1%.

Risky Drugs to Seniors

2% of this provider’s 2,843 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 3%.

Brand Name Drugs

28% of this provider’s prescriptions were for brand-name drugs, compared to an average of 26%.

Prescription Price

$128 was the average price of a prescription from this provider, compared to $130 among peers.

Prescriptions per Patient

23 is the average number of prescriptions (including refills) per patient, compared to an average of 14.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Louisiana
TRAZODONE HCL 932 184 1 1
CYMBALTA 833 168 2 5
ZOLPIDEM TARTRATE 706 111 3 11
QUETIAPINE FUMARATE 636 133 4 3
LAMOTRIGINE 629 135 5 16
DIVALPROEX SODIUM ER 559 79 6 6
RISPERIDONE 524 186 7 2
HYDROCODONE-ACETAMINOPHEN 426 26 S3 8 41
ABILIFY 363 59 9 10
CITALOPRAM HBR 361 93 10 8
ESCITALOPRAM OXALATE 322 72 11 15
SEROQUEL 317 52 12 17
FLUOXETINE HCL 302 31 13 12
VENLAFAXINE HCL ER 298 66 14 14
OXCARBAZEPINE 297 44 15 30
BENZTROPINE MESYLATE 264 28 R 16 4
SERTRALINE HCL 261 80 17 7
MIRTAZAPINE 260 93 18 9
AMPHETAMINE SALT COMBO 218 0 S2 19 45
LITHIUM CARBONATE 199 33 20 18
OLANZAPINE 193 59 21 13
SEROQUEL XR 193 11 21 22
CARISOPRODOL 184 0 R 23 93
DONEPEZIL HCL 158 147 24 27
INVEGA 155 16 25 34
NAMENDA 149 93 26 21
PAROXETINE HCL 147 37 27 25
ZIPRASIDONE HCL 144 0 28 24
METHYLPHENIDATE HCL 121 40 29 72
GABAPENTIN 118 28 30 31
LEXAPRO 115 16 31 51
BUPROPION XL 111 0 32 19
IMIPRAMINE HCL 108 18 R 33 81
INVEGA SUSTENNA 103 0 34 33
BUPROPION HCL SR 96 0 35 32
HALOPERIDOL 93 12 36 23
PRISTIQ ER 91 0 37 36
VYVANSE 90 0 S2 38 115
AMITRIPTYLINE HCL 90 0 R 38 38
OMEPRAZOLE 86 15 40 35
BUSPIRONE HCL 85 0 41 26
TOPIRAMATE 80 0 42 36
HYDROXYZINE PAMOATE 80 0 R 42 29
DOXEPIN HCL 77 0 44 48
CLOZAPINE 75 59 45 28
LATUDA 74 0 46 56
TRAMADOL HCL 74 0 46 62
EXELON 71 49 48 46
CARBAMAZEPINE 70 12 49 43
CLONIDINE HCL 60 13 50 52
DEXTROAMPHETAMINE-AMPHETAMINE 60 0 S2 50 105
LUNESTA 50 0 52 73
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on July 3, 2008.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.